| Literature DB >> 27829148 |
Ferdinando Pucci1, Steffen Rickelt2, Andita P Newton1, Christopher Garris3, Ernesto Nunes4, Charles Evavold3, Christina Pfirschke1, Camilla Engblom3, Mari Mino-Kenudson5, Richard O Hynes2, Ralph Weissleder6, Mikael J Pittet7.
Abstract
Co-option of host components by solid tumors facilitates cancer progression and can occur in both local tumor microenvironments and remote locations. At present, the signals involved in long-distance communication remain insufficiently understood. Here, we identify platelet factor 4 (PF4, CXCL4) as an endocrine factor whose overexpression in tumors correlates with decreased overall patient survival. Furthermore, engineered PF4 over-production in a Kras-driven lung adenocarcinoma genetic mouse model expanded megakaryopoiesis in bone marrow, augmented platelet accumulation in lungs, and accelerated de novo adenocarcinogenesis. Additionally, anti-platelet treatment controlled mouse lung cancer progression, further suggesting that platelets can modulate the tumor microenvironment to accelerate tumor outgrowth. These findings support PF4 as a cancer-enhancing endocrine signal that controls discrete aspects of bone marrow hematopoiesis and tumor microenvironment and that should be considered as a molecular target in anticancer therapy.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27829148 PMCID: PMC5108525 DOI: 10.1016/j.celrep.2016.10.031
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423